AstraZeneca Seeks F.D.A. Approval for Covid Antibody Treatment

The company said the treatment had cut the risk of symptomatic Covid in patients with conditions that put them at high risk, or who had not responded well to a vaccine.The company said the treatment had cut the risk of symptomatic Covid in patients with conditions that put them at high risk, or who had not responded well to a vaccine.

Leave a Reply